Objectives To describe hospital economic burden of microcrystal arthropathies in France from 2010 to 2012 using French Hospital National Database

Methods Data were extracted from the French Hospital National Database. We selected all adult (age >18 years) hospitalizations for crystal arthropathies encoded as primary diagnosis with their corresponding ICD-10 codes. Hospital stays were classified in those related to gout, chrondrocalcinosis, or other crystal arthropathies. For each type of crystals arthropathies, we have numbered the hospitalizations, and have described the mean age and percentage of women, the mean duration of stay, and the following diagnoses encoded as secondary diagnosis either related to the metabolic syndrome (diabetes, dysplipidemia, obesity, hypertension) or to other relevant comorbidities (ischemic cardiac disease, chronic renal insufficiency, cerebrovascular disease).

For economic evaluation, we used the 2012 public tariff per disease related group and did not take into account the costs related to prosthesis or materiel of osteosynthesis in the case of surgical management or those due to dialysis or stay in intensive care. The point of view is those of society.

Results there were 137,734 hospitalizations involving 105,932 patients (61% for gout, 34% chondrocalcinosis, and 5% other microcrystal arthropathies). Patients with chondrocalcinosis diagnosis were older (mean age of 77.3 years versus 74.8 for other microcrystals and 72.5 for gout). Men represented 73%, 37% and 48% of the patients with gout, chondrocalcinosis and other microcrystal arthropathies, respectively. Hypertension, diabetes, dyslipidemia, cardiac ischemia, and renal failure were more frequent in patients with gout than other patients (table 1). The overall hospital costs were 562 million Euros, 71% spent on gout patients.

Conclusions In terms of hospital costs, gout represented the main part of the economic burden of crystal arthropathies and a high level of diseases belonging to the metabolic syndrome. Specific therapy programs favouring adherence to treatment could diminish this hospital economic burden.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.4776